Presentations Eledon Corporate Presentation Eledon Pharmaceuticals Phase 2 BESTOW Tegoprubart Data at Kidney Week 2025 Updated Data from Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation Eledon Pharmaceuticals R&D Day Presentation – July 9, 2025 Publications American Society of Transplant Surgeons Winter Symposium, January 23, 2026: Long-Term Outcomes of a Phase 1, Single-Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen American Journal of Transplantation: December 24, 2025 Gene-edited pig cardiac xenotransplantation as a bridge to allotransplantation in infants: Progress in a pig-to-baboon model The New England Journal of Medicine: February 7, 2025: Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease Nature Medicine Jan 8, 2025: Transplantation of a genetically modified porcine heart into a live human American Transplant Congress, June 1-5, 2024, Biomarkers of Inflammation and eGFR in an Ongoing Phase 1B Study of an Anti-CD40L Antibody Tegoprubart, For The Prevention of Rejection In Kidney Transplant Science Translational Medicine August 30, 2023: The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates Frontiers in Immunology April 7, 2022: The Inhibition of CD40/CD154 Costimulatory Signaling in the Prevention of Renal Transplant Rejection in Nonhuman Primates: A Systematic Review and Meta Analysis
